Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brands Push Back Against REMS Reform, Call Problem Small With Burdensome Fixes

Executive Summary

BIO cautioned that its members may have difficulties meeting the purchase orders of product for generic sponsors, while PhRMA contended legislation is not necessary.

You may also be interested in...



REMS Abuse Website: Has It Changed The Behavior Of Innovators?

Updated numbers from the US FDA's REMS abuse website show that Celgene has received two additional safety determination letters, raising question's about whether the public list has changed the practices of brand companies hindering generic company access to samples.

Invitation Accepted: Biopharma Leaders Will Testify At Senate Hearing On Pricing

In addition to fielding tough questions about pricing practices at the session, executives may announce new voluntary efforts to lower drug costs and will offer their own ideas for legislation.

Lilly CEO Breaks From PhRMA, Innovators With Support For CREATES Act

Legislation that would prevent REMS from blocking generics appears to be gaining momentum.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel